Grant: Collaborative Research and Development Grants
Université de Sherbrooke
$185,455.00
Can deep-learning algorithms identify genetic mutations or aberrant cellular signalling pathways from medical images?
FY 2019-20
Summary
Our project will determine if cancer-related genetic mutations found in tumours can be detected using medicalimaging. Tumours arise from a series of genetic errors, and these determine much of the behaviour of a tumour,including its aggressiveness and its response to a treatment. In day-to-day medical imaging, once a patient hasundergone a medical scan, a specialist will look at the images and provide a diagnosis (e.g., liver cancer).Sometimes, a biopsy (tumour sample) is acquired to better determine the subtype of cancer. Our project aims atassisting physicians by providing them with additional information extracted using artificial intelligence andadvanced computer software. These are already known to be superior to humans in finding and quantifyingsubtle image characteristics. We hypothesize that these image characteristics could be predictive of the cancersubtype and its optimal treatment. First, this software has to be trained to recognize mutations. Because humantumours vary a lot, it is difficult to differentiate visual characteristics caused by an individual inherentvariability from those caused by the mutation. To overcome this, we will use genetically engineered mousemodels - these will have specific mutations that will result in cancer but with limited variability betweenanimals. This will allow us to train a software to recognize tumours that have specific mutations. If successful,our project will ultimately lead to software tools with capabilities similar to biopsies, and better and lessinvasive management of cancer.
Program
Collaborative Research and Development Grants
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
531111-2018
Name nom
Lepage, Martin
Department département
Médecine nucléaire et radiobiologie
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2018
Award amount
185455
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3115
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Medical Physics
Research subject fr
Physique médicale
Installment
inst:2 - 2
Partie
2
Nb partie
2
Application title
Can deep-learning algorithms identify genetic mutations or aberrant cellular signalling pathways from medical images?
Keyword
NSERC
Application summary
Our project will determine if cancer-related genetic mutations found in tumours can be detected using medicalimaging. Tumours arise from a series of genetic errors, and these determine much of the behaviour of a tumour,including its aggressiveness and its response to a treatment. In day-to-day medical imaging, once a patient hasundergone a medical scan, a specialist will look at the images and provide a diagnosis (e.g., liver cancer).Sometimes, a biopsy (tumour sample) is acquired to better determine the subtype of cancer. Our project aims atassisting physicians by providing them with additional information extracted using artificial intelligence andadvanced computer software. These are already known to be superior to humans in finding and quantifyingsubtle image characteristics. We hypothesize that these image characteristics could be predictive of the cancersubtype and its optimal treatment. First, this software has to be trained to recognize mutations. Because humantumours vary a lot, it is difficult to differentiate visual characteristics caused by an individual inherentvariability from those caused by the mutation. To overcome this, we will use genetically engineered mousemodels - these will have specific mutations that will result in cancer but with limited variability betweenanimals. This will allow us to train a software to recognize tumours that have specific mutations. If successful,our project will ultimately lead to software tools with capabilities similar to biopsies, and better and lessinvasive management of cancer.